Effects  ||| S:0 E:8 ||| NNS
of  ||| S:8 E:11 ||| IN
paliperidone  ||| S:11 E:24 ||| JJ
extended  ||| S:24 E:33 ||| JJ
release  ||| S:33 E:41 ||| NN
on  ||| S:41 E:44 ||| IN
functioning  ||| S:44 E:56 ||| VBG
level  ||| S:56 E:62 ||| NN
and  ||| S:62 E:66 ||| CC
symptoms  ||| S:66 E:75 ||| NNS
of  ||| S:75 E:78 ||| IN
patients  ||| S:78 E:87 ||| NNS
with  ||| S:87 E:92 ||| IN
recent  ||| S:92 E:99 ||| JJ
onset  ||| S:99 E:105 ||| NN
schizophrenia ||| S:105 E:118 ||| NN
:  ||| S:118 E:120 ||| :
An  ||| S:120 E:123 ||| DT
open-label ||| S:123 E:133 ||| JJ
,  ||| S:133 E:135 ||| ,
single-arm ||| S:135 E:145 ||| NNP
,  ||| S:145 E:147 ||| ,
flexible-dose ||| S:147 E:160 ||| NNP
,  ||| S:160 E:162 ||| ,
12-months  ||| S:162 E:172 ||| CD
follow-up  ||| S:172 E:182 ||| JJ
study  ||| S:182 E:188 ||| NN
Response  ||| S:188 E:197 ||| NNP
to  ||| S:197 E:200 ||| TO
antipsychotic  ||| S:200 E:214 ||| VB
treatment  ||| S:214 E:224 ||| NN
is  ||| S:224 E:227 ||| VBZ
better  ||| S:227 E:234 ||| JJR
in  ||| S:234 E:237 ||| IN
the  ||| S:237 E:241 ||| DT
early  ||| S:241 E:247 ||| JJ
stages  ||| S:247 E:254 ||| NNS
of  ||| S:254 E:257 ||| IN
schizophrenia ||| S:257 E:270 ||| NN
.  ||| S:270 E:272 ||| .
The  ||| S:272 E:276 ||| DT
primary  ||| S:276 E:284 ||| JJ
objective  ||| S:284 E:294 ||| NN
of  ||| S:294 E:297 ||| IN
this  ||| S:297 E:302 ||| DT
non-randomized ||| S:302 E:316 ||| JJ
,  ||| S:316 E:318 ||| ,
single-arm ||| S:318 E:328 ||| NNP
,  ||| S:328 E:330 ||| ,
multicenter  ||| S:330 E:342 ||| JJ
clinical  ||| S:342 E:351 ||| JJ
trial  ||| S:351 E:357 ||| NN
was  ||| S:357 E:361 ||| VBD
to  ||| S:361 E:364 ||| TO
explore  ||| S:364 E:372 ||| VB
the  ||| S:372 E:376 ||| DT
response  ||| S:376 E:385 ||| NN
to  ||| S:385 E:388 ||| TO
treatment  ||| S:388 E:398 ||| NN
and  ||| S:398 E:402 ||| CC
safety  ||| S:402 E:409 ||| NN
of  ||| S:409 E:412 ||| IN
a  ||| S:412 E:414 ||| DT
flexible  ||| S:414 E:423 ||| JJ
dose  ||| S:423 E:428 ||| NN
of  ||| S:428 E:431 ||| IN
paliperidone  ||| S:431 E:444 ||| NNS
( ||| S:444 E:445 ||| -LRB-
mean  ||| S:445 E:450 ||| NN
=  ||| S:450 E:452 ||| SYM
6.42  ||| S:452 E:457 ||| FW
mg ||| S:457 E:459 ||| FW
/ ||| S:459 E:460 ||| FW
day ||| S:460 E:463 ||| NN
)  ||| S:463 E:465 ||| -RRB-
in  ||| S:465 E:468 ||| IN
patients  ||| S:468 E:477 ||| NNS
with  ||| S:477 E:482 ||| IN
recent  ||| S:482 E:489 ||| JJ
onset  ||| S:489 E:495 ||| NN
schizophrenia  ||| S:495 E:509 ||| NN
(  ||| S:509 E:510 ||| -LRB-
< ||| S:510 E:512 ||| SYM
3  ||| S:512 E:514 ||| CD
years  ||| S:514 E:520 ||| NNS
after  ||| S:520 E:526 ||| IN
the  ||| S:526 E:530 ||| DT
first  ||| S:530 E:536 ||| JJ
episode ||| S:536 E:543 ||| NN
/ ||| S:543 E:544 ||| CD
hospitalization ||| S:544 E:559 ||| NN
) ||| S:559 E:560 ||| -RRB-
.  ||| S:560 E:562 ||| .
Severity  ||| S:562 E:571 ||| NN
of  ||| S:571 E:574 ||| IN
clinical  ||| S:574 E:583 ||| JJ
symptoms  ||| S:583 E:592 ||| NNS
was  ||| S:592 E:596 ||| VBD
evaluated  ||| S:596 E:606 ||| VBN
by  ||| S:606 E:609 ||| IN
the  ||| S:609 E:613 ||| DT
Positive  ||| S:613 E:622 ||| JJ
and  ||| S:622 E:626 ||| CC
Negative  ||| S:626 E:635 ||| NNP
Syndrome  ||| S:635 E:644 ||| NNP
Scale  ||| S:644 E:650 ||| NNP
( ||| S:650 E:651 ||| -LRB-
PANSS ||| S:651 E:656 ||| NNP
) ||| S:656 E:657 ||| -RRB-
,  ||| S:657 E:659 ||| ,
functioning  ||| S:659 E:671 ||| VBG
was  ||| S:671 E:675 ||| VBD
assessed  ||| S:675 E:684 ||| VBN
using  ||| S:684 E:690 ||| VBG
the  ||| S:690 E:694 ||| DT
Global  ||| S:694 E:701 ||| NNP
Assessment  ||| S:701 E:712 ||| NNP
of  ||| S:712 E:715 ||| IN
Functioning  ||| S:715 E:727 ||| NNP
( ||| S:727 E:728 ||| -LRB-
GAF ||| S:728 E:731 ||| NNP
)  ||| S:731 E:733 ||| -RRB-
scale  ||| S:733 E:739 ||| NN
and  ||| S:739 E:743 ||| CC
the  ||| S:743 E:747 ||| DT
Personal  ||| S:747 E:756 ||| JJ
and  ||| S:756 E:760 ||| CC
Social  ||| S:760 E:767 ||| NNP
Performance  ||| S:767 E:779 ||| NNP
Scale  ||| S:779 E:785 ||| NNP
( ||| S:785 E:786 ||| -LRB-
PSP ||| S:786 E:789 ||| NNP
) ||| S:789 E:790 ||| -RRB-
.  ||| S:790 E:792 ||| .
In  ||| S:792 E:795 ||| IN
a  ||| S:795 E:797 ||| DT
total  ||| S:797 E:803 ||| NN
of  ||| S:803 E:806 ||| IN
85  ||| S:806 E:809 ||| CD
patients  ||| S:809 E:818 ||| NNS
enrolled ||| S:818 E:826 ||| VBD
,  ||| S:826 E:828 ||| ,
80  ||| S:828 E:831 ||| CD
patients  ||| S:831 E:840 ||| NNS
were  ||| S:840 E:845 ||| VBD
eligible ||| S:845 E:853 ||| JJ
.  ||| S:853 E:855 ||| .
Total  ||| S:855 E:861 ||| JJ
PSP  ||| S:861 E:865 ||| NNP
score  ||| S:865 E:871 ||| NN
at  ||| S:871 E:874 ||| IN
baseline  ||| S:874 E:883 ||| NN
( ||| S:883 E:884 ||| -LRB-
50.2  ||| S:884 E:889 ||| CD
±  ||| S:889 E:891 ||| CD
11.6 ||| S:891 E:895 ||| CD
)  ||| S:895 E:897 ||| -RRB-
increased  ||| S:897 E:907 ||| VBD
at  ||| S:907 E:910 ||| IN
all  ||| S:910 E:914 ||| DT
visits ||| S:914 E:920 ||| NNS
.  ||| S:920 E:922 ||| .
Total  ||| S:922 E:928 ||| JJ
PSP  ||| S:928 E:932 ||| NNP
score  ||| S:932 E:938 ||| NN
was  ||| S:938 E:942 ||| VBD
65.4  ||| S:942 E:947 ||| CD
±  ||| S:947 E:949 ||| CD
12.1  ||| S:949 E:954 ||| CD
at  ||| S:954 E:957 ||| IN
month  ||| S:957 E:963 ||| NN
12  ||| S:963 E:966 ||| CD
( ||| S:966 E:967 ||| -LRB-
P  ||| S:967 E:969 ||| NNP
< ||| S:969 E:971 ||| SYM
0.001 ||| S:971 E:976 ||| NNP
) ||| S:976 E:977 ||| -RRB-
.  ||| S:977 E:979 ||| .
GAF  ||| S:979 E:983 ||| NNP
scores  ||| S:983 E:990 ||| NNS
were  ||| S:990 E:995 ||| VBD
significantly  ||| S:995 E:1009 ||| RB
higher  ||| S:1009 E:1016 ||| JJR
at  ||| S:1016 E:1019 ||| IN
all  ||| S:1019 E:1023 ||| DT
visits  ||| S:1023 E:1030 ||| NNS
compared  ||| S:1030 E:1039 ||| VBN
with  ||| S:1039 E:1044 ||| IN
baseline  ||| S:1044 E:1053 ||| NN
( ||| S:1053 E:1054 ||| -LRB-
P  ||| S:1054 E:1056 ||| NN
=  ||| S:1056 E:1058 ||| SYM
0.001 ||| S:1058 E:1063 ||| CD
) ||| S:1063 E:1064 ||| -RRB-
.  ||| S:1064 E:1066 ||| .
It  ||| S:1066 E:1069 ||| PRP
was  ||| S:1069 E:1073 ||| VBD
62.4  ||| S:1073 E:1078 ||| CD
±  ||| S:1078 E:1080 ||| CD
12.5  ||| S:1080 E:1085 ||| CD
with  ||| S:1085 E:1090 ||| IN
an  ||| S:1090 E:1093 ||| DT
increase  ||| S:1093 E:1102 ||| NN
of  ||| S:1102 E:1105 ||| IN
42.9 ||| S:1105 E:1109 ||| CD
%  ||| S:1109 E:1111 ||| NN
at  ||| S:1111 E:1114 ||| IN
month  ||| S:1114 E:1120 ||| NN
12  ||| S:1120 E:1123 ||| CD
( ||| S:1123 E:1124 ||| -LRB-
P  ||| S:1124 E:1126 ||| NNP
< ||| S:1126 E:1128 ||| SYM
0.001 ||| S:1128 E:1133 ||| NNP
) ||| S:1133 E:1134 ||| -RRB-
.  ||| S:1134 E:1136 ||| .
PANSS  ||| S:1136 E:1142 ||| NNP
Positive  ||| S:1142 E:1151 ||| NNP
and  ||| S:1151 E:1155 ||| CC
Negative  ||| S:1155 E:1164 ||| JJ
subscales  ||| S:1164 E:1174 ||| NN
and  ||| S:1174 E:1178 ||| CC
General  ||| S:1178 E:1186 ||| NNP
psychopathology  ||| S:1186 E:1202 ||| VBD
subscale  ||| S:1202 E:1211 ||| JJ
scores  ||| S:1211 E:1218 ||| NNS
showed  ||| S:1218 E:1225 ||| VBD
significant  ||| S:1225 E:1237 ||| JJ
reductions  ||| S:1237 E:1248 ||| NNS
beginning  ||| S:1248 E:1258 ||| VBG
with  ||| S:1258 E:1263 ||| IN
month  ||| S:1263 E:1269 ||| NN
3  ||| S:1269 E:1271 ||| CD
and  ||| S:1271 E:1275 ||| CC
were  ||| S:1275 E:1280 ||| VBD
11.9  ||| S:1280 E:1285 ||| CD
±  ||| S:1285 E:1287 ||| CD
3.8  ||| S:1287 E:1291 ||| CD
( ||| S:1291 E:1292 ||| -LRB-
29.3 ||| S:1292 E:1296 ||| CD
% ||| S:1296 E:1297 ||| NN
;  ||| S:1297 E:1299 ||| :
P  ||| S:1299 E:1301 ||| NNP
< ||| S:1301 E:1303 ||| SYM
0.001 ||| S:1303 E:1308 ||| NNP
) ||| S:1308 E:1309 ||| -RRB-
,  ||| S:1309 E:1311 ||| ,
13.7  ||| S:1311 E:1316 ||| CD
±  ||| S:1316 E:1318 ||| CD
5.6  ||| S:1318 E:1322 ||| CD
( ||| S:1322 E:1323 ||| -LRB-
27.3 ||| S:1323 E:1327 ||| NNP
%  ||| S:1327 E:1329 ||| NN
P  ||| S:1329 E:1331 ||| NN
< ||| S:1331 E:1333 ||| SYM
0.001 ||| S:1333 E:1338 ||| CD
)  ||| S:1338 E:1340 ||| -RRB-
and  ||| S:1340 E:1344 ||| CC
27.8  ||| S:1344 E:1349 ||| CD
±  ||| S:1349 E:1351 ||| CD
7.1  ||| S:1351 E:1355 ||| CD
( ||| S:1355 E:1356 ||| -LRB-
23.2 ||| S:1356 E:1360 ||| CD
% ||| S:1360 E:1361 ||| NN
;  ||| S:1361 E:1363 ||| :
P  ||| S:1363 E:1365 ||| NNP
< ||| S:1365 E:1367 ||| SYM
0.001 ||| S:1367 E:1372 ||| NNP
)  ||| S:1372 E:1374 ||| -RRB-
at  ||| S:1374 E:1377 ||| IN
month  ||| S:1377 E:1383 ||| NN
12 ||| S:1383 E:1385 ||| CD
,  ||| S:1385 E:1387 ||| ,
respectively ||| S:1387 E:1399 ||| RB
.  ||| S:1399 E:1401 ||| .
Twelve  ||| S:1401 E:1408 ||| CD
patients  ||| S:1408 E:1417 ||| NNS
( ||| S:1417 E:1418 ||| -LRB-
14.3 ||| S:1418 E:1422 ||| CD
% ||| S:1422 E:1423 ||| NN
)  ||| S:1423 E:1425 ||| -RRB-
had  ||| S:1425 E:1429 ||| VBD
a  ||| S:1429 E:1431 ||| DT
serious  ||| S:1431 E:1439 ||| JJ
adverse  ||| S:1439 E:1447 ||| JJ
event ||| S:1447 E:1452 ||| NN
.  ||| S:1452 E:1454 ||| .
The  ||| S:1454 E:1458 ||| DT
most  ||| S:1458 E:1463 ||| RBS
common  ||| S:1463 E:1470 ||| JJ
adverse  ||| S:1470 E:1478 ||| JJ
events  ||| S:1478 E:1485 ||| NNS
were  ||| S:1485 E:1490 ||| VBD
insomnia  ||| S:1490 E:1499 ||| NNS
( ||| S:1499 E:1500 ||| -LRB-
17.9 ||| S:1500 E:1504 ||| CD
% ||| S:1504 E:1505 ||| NN
) ||| S:1505 E:1506 ||| -RRB-
,  ||| S:1506 E:1508 ||| ,
nausea  ||| S:1508 E:1515 ||| NNS
( ||| S:1515 E:1516 ||| -LRB-
8.3 ||| S:1516 E:1519 ||| CD
% ||| S:1519 E:1520 ||| NN
) ||| S:1520 E:1521 ||| -RRB-
,  ||| S:1521 E:1523 ||| ,
akathisia  ||| S:1523 E:1533 ||| NNS
( ||| S:1533 E:1534 ||| -LRB-
4.8 ||| S:1534 E:1537 ||| CD
% ||| S:1537 E:1538 ||| NN
) ||| S:1538 E:1539 ||| -RRB-
,  ||| S:1539 E:1541 ||| ,
anxiety  ||| S:1541 E:1549 ||| NN
( ||| S:1549 E:1550 ||| -LRB-
4.8 ||| S:1550 E:1553 ||| CD
% ||| S:1553 E:1554 ||| NN
)  ||| S:1554 E:1556 ||| -RRB-
and  ||| S:1556 E:1560 ||| CC
depression  ||| S:1560 E:1571 ||| NN
( ||| S:1571 E:1572 ||| -LRB-
4.8 ||| S:1572 E:1575 ||| CD
% ||| S:1575 E:1576 ||| NN
) ||| S:1576 E:1577 ||| -RRB-
.  ||| S:1577 E:1579 ||| .
Body  ||| S:1579 E:1584 ||| NN
weight  ||| S:1584 E:1591 ||| NN
values  ||| S:1591 E:1598 ||| NNS
at  ||| S:1598 E:1601 ||| IN
the  ||| S:1601 E:1605 ||| DT
end  ||| S:1605 E:1609 ||| NN
of  ||| S:1609 E:1612 ||| IN
the  ||| S:1612 E:1616 ||| DT
study  ||| S:1616 E:1622 ||| NN
were  ||| S:1622 E:1627 ||| VBD
significantly  ||| S:1627 E:1641 ||| RB
higher  ||| S:1641 E:1648 ||| RBR
compared  ||| S:1648 E:1657 ||| VBN
with  ||| S:1657 E:1662 ||| IN
baseline ||| S:1662 E:1670 ||| NN
.  ||| S:1670 E:1672 ||| .
The  ||| S:1672 E:1676 ||| DT
present  ||| S:1676 E:1684 ||| JJ
study  ||| S:1684 E:1690 ||| NN
demonstrates  ||| S:1690 E:1703 ||| VBZ
that  ||| S:1703 E:1708 ||| DT
flexible  ||| S:1708 E:1717 ||| JJ
dose  ||| S:1717 E:1722 ||| NN
of  ||| S:1722 E:1725 ||| IN
paliperidone  ||| S:1725 E:1738 ||| NN
resulted  ||| S:1738 E:1747 ||| VBD
in  ||| S:1747 E:1750 ||| IN
a  ||| S:1750 E:1752 ||| DT
significant  ||| S:1752 E:1764 ||| JJ
improvement  ||| S:1764 E:1776 ||| NN
in  ||| S:1776 E:1779 ||| IN
functioning  ||| S:1779 E:1791 ||| VBG
and  ||| S:1791 E:1795 ||| CC
reduction  ||| S:1795 E:1805 ||| NN
in  ||| S:1805 E:1808 ||| IN
symptoms  ||| S:1808 E:1817 ||| NNS
in  ||| S:1817 E:1820 ||| IN
patients  ||| S:1820 E:1829 ||| NNS
with  ||| S:1829 E:1834 ||| IN
recent  ||| S:1834 E:1841 ||| JJ
onset  ||| S:1841 E:1847 ||| NN
schizophrenia ||| S:1847 E:1860 ||| NN
.  ||| S:1860 E:1862 ||| .
